Generic Name: patiromer
Brand Name: Veltassa
Manufacturer: Otsuka Canada Pharmaceuticals Inc.
Therapeutic Area: Hyperkalemia, adults (chronic kidney disease)
Indications: For the treatment of hyperkalemia in adults with chronic kidney disease (eGFR ≥15mL/min/1.73m).
Manufacturer Requested Reimbursement Criteria1: For the treatment of hyperkalemia in adults with CKD 3-4 on RAASi therapy.
Submission Type: Initial
NOC Status at Filing: Post NOC
Project Status: Active
Companion Diagnostics: No
Fee Schedule: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
|Call for patient/clinician input open||October 02, 2020|
|Call for patient/clinician input closed||November 23, 2020|
- Patient input submission received from the The Kidney Foundation of Canada
|Submission received||October 30, 2020|
|Submission accepted||November 13, 2020|
|Review initiated||November 16, 2020|
|Draft CADTH review report(s) provided to sponsor for comment||February 25, 2021|
|Deadline for sponsors comments||March 08, 2021|
|CADTH responses on draft review report(s) provided to sponsor||April 09, 2021|
|Expert committee meeting (initial)||April 21, 2021|
|Draft recommendation issued to sponsor||May 03, 2021|
|Draft recommendation posted for stakeholder feedback||May 13, 2021|
|End of feedback period||May 28, 2021|
|Final recommendation issued to sponsor and drug plans||June 08, 2021|
|Final recommendation posted||June 24, 2021|
|Deadline for sponsor to submit redaction requests on draft CADTH review report(s)||June 22, 2021|
|CADTH review report(s) posted||-|